ARCHIVES

51% Control Rate Achieved In Phase II Trial of Elderly Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

January 31, 2014

Non-Profit Spent $1.3 Million On Consultants.

March 28, 2008

In Brief: Ross, Harvey To Lead Cancer Center Group; NCI Director In Office By Aug. 1, Varmus Says

May 19, 1995

Tobacco Control Bill Requires Stronger Warnings

August 10, 1990

Canadian Products Anticancer Drugs In Plant Culture

April 22, 1983

Cancer Center Directors Say Collaboration, Funding, and Application of Best Practices Will Reduce the Burden of Cancer.

September 15, 2006